Orum Therapeutics Inc banner
O

Orum Therapeutics Inc
KOSDAQ:475830

Watchlist Manager
Orum Therapeutics Inc
KOSDAQ:475830
Watchlist
Price: 126 300 KRW 1.12% Market Closed
Market Cap: ₩2.7T

Orum Therapeutics Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Orum Therapeutics Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
O
Orum Therapeutics Inc
KOSDAQ:475830
Other Items
-₩97.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Other Items
-₩14.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
OliX Pharmaceuticals Inc
KOSDAQ:226950
Other Items
-₩97.3B
CAGR 3-Years
-57%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Other Items
₩23.5B
CAGR 3-Years
N/A
CAGR 5-Years
19%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Other Items
-₩202.5B
CAGR 3-Years
N/A
CAGR 5-Years
-48%
CAGR 10-Years
-26%
A
ABL Bio Inc
KOSDAQ:298380
Other Items
₩3.1B
CAGR 3-Years
-46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orum Therapeutics Inc
Glance View

Market Cap
2.7T KRW
Industry
Biotechnology

Orum Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2025-02-14. The firm is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Intrinsic Value
800.61 KRW
Overvaluation 99%
Intrinsic Value
Price
O

See Also

What is Orum Therapeutics Inc's Other Items?
Other Items
-97.2B KRW

Based on the financial report for Dec 31, 2024, Orum Therapeutics Inc's Other Items amounts to -97.2B KRW.

What is Orum Therapeutics Inc's Other Items growth rate?
Other Items CAGR 1Y
-7 382%

Over the last year, the Other Items growth was -7 382%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett